BCC 2021 | monarchE: adjuvant abemaciclib in HR+ breast cancer

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, describes the results of monarchE (NCT03155997), a Phase III study evaluating the use of endocrine therapy with or without abemaciclib, a CDK4/6 inhibitor following surgery in patients with high-risk, node-positive, early-stage, hormone receptor-positive (HR+) breast cancer. The results of this study suggest that the abemaciclib treatment arm showed improved outcomes in patients with hormone-receptor-positive breast cancer. This interview took place during the 17th St. Gallen International Breast Cancer Conference.